import{_ as i}from"./plugin-vue_export-helper-DlAUqK2U.js";import{c as r,a as o,g as n,d as t,f as a,w as s,r as u,b as g}from"./app-DGckflSM.js";const p={};function c(d,e){const l=u("think");return g(),r("div",null,[o(l,null,{default:s(()=>[...e[0]||(e[0]=[n(` We are summarizing Chapter 22 "Target Trial Emulation" from the provided PDF content. The chapter has several sections and fine points. We'll break it down step by step. `,-1),t("p",null,"Steps:",-1),t("ol",null,[t("li",null,"Identify the main sections and subsections."),t("li",null,"Extract technical points and fine points."),t("li",null,"Summarize the content in the required format.")],-1),t("p",null,"The chapter has:",-1),t("ul",null,[t("li",null,"22.1 Intention-to-treat effect and per-protocol effect"),t("li",null,"Fine Point 22.1: The exclusion restriction (again)"),t("li",null,"Fine Point 22.2: Pseudo-intention-to-treat analysis and modified intention-to-treat analysis"),t("li",null,"Fine Point 22.3: Naïve per-protocol analyses"),t("li",null,"Fine Point 22.4: More misunderstandings about the intention-to-treat effect"),t("li",null,"22.2 A target trial with sustained treatment strategies"),t("li",null,"Technical Point 22.1: Controlled direct effects"),t("li",null,"Technical Point 22.2: Pure direct effects and principal stratum direct effects"),t("li",null,"22.3 Emulating a target trial with sustained strategies"),t("li",null,"22.4 Time zero"),t("li",null,"Fine Point 22.5: Grace periods"),t("li",null,"22.5 A unified approach to answer What If questions with data"),t("li",null,"Fine Point 22.6: How do the data of randomized experiments and observational studies differ?"),t("li",null,"Fine Point 22.7: A counterintuitive comparison of a randomized trial and an observational study"),t("li",null,"Fine Point 22.8: Generalizing Fine Point 22.7 to realistic settings")],-1),t("p",null,"However, note that the provided text ends at page 18 and we have to base our summary on the provided text.",-1),t("p",null,"We'll structure the summary by the main sections and include the fine points and technical points as sub-sections.",-1),t("p",null,"Important: We must use the exact structure and terminology from the text.",-1),t("p",null,"Let's begin.",-1)])]),_:1}),e[1]||(e[1]=n(" ### Chapter 22: TARGET TRIAL EMULATION ",-1)),e[2]||(e[2]=t("h4",{id:"_22-1-intention-to-treat-effect-and-per-protocol-effect",tabindex:"-1"},[t("a",{class:"header-anchor",href:"#_22-1-intention-to-treat-effect-and-per-protocol-effect"},[t("span",null,"22.1 Intention-to-treat effect and per-protocol effect")])],-1)),e[3]||(e[3]=t("p",null,[t("strong",null,"Technical Points"),n(":")],-1)),e[4]||(e[4]=t("ul",null,[t("li",null,[t("strong",null,"核心理论"),n(": "),t("ul",null,[t("li",null,"观察性研究中的因果推断可视为对假设性随机试验（目标试验）的模仿。"),t("li",null,"意向治疗效应（ITT）定义为分配治疗（Z）对结局（Y）的因果效应，通过路径 Z→A→Y（治疗接受）和 Z→Y（行为变化）实现。"),t("li",null,"方案效应（Per-Protocol Effect）定义为所有个体完全遵守分配策略时的因果效应，需调整时间依赖性混杂。")])]),t("li",null,[t("strong",null,"关键公式"),n(": "),t("ul",null,[t("li",null,[n("ITT风险比：$$ \\frac{\\text{Pr}[Y=1|Z=1]}{\\text{Pr}[Y=1|Z=0]} = \\frac{\\text{Pr}[Y"),t("sup",{z:"0"},"{z=1}=1]}{\\text{Pr}[Y"),n("=1]} $$")]),t("li",null,[n("方案效应风险比：$$ \\frac{\\text{Pr}[Y"),t("sup",{a:"0"},"{a=1}=1]}{\\text{Pr}[Y"),n("=1]} $$（在排除限制下）")])])]),t("li",null,[t("strong",null,"重要概念"),n(": "),t("ul",null,[t("li",null,[t("strong",null,"排除限制"),n("：当不存在直接路径 Z→Y 时成立（图22.2），双盲安慰剂试验可强制实现。")]),t("li",null,[t("strong",null,"交换性"),n("：随机分配确保 ITT 无混杂（Yᶻ⊥⊥Z），但方案效应需调整混杂（如未测量风险因素U）。")])])]),t("li",null,[t("strong",null,"应用场景"),n(": "),t("ul",null,[t("li",null,"ITT 用于随机试验的初级分析，方案效应用于评估实际治疗效果（如药物安全性评估）。")])])],-1)),e[5]||(e[5]=a('<p><strong>细节要点</strong>:</p><ul><li><strong>案例分析</strong>：疫苗试验中，高风险个体（U=1）在对照组可能自行接种（A=1），导致传统&quot;按治疗&quot;分析（A=1 vs A=0）因混杂偏倚无效。</li><li><strong>辅助信息</strong>: <ul><li>伪ITT分析（仅纳入未失访者）和改良ITT分析（仅纳入初始治疗者）可能因选择偏倚导致估计偏差。</li><li>传统方案分析（仅纳入遵守者）因忽略时间依赖性混杂（图22.4路径 Z→A←L←U→Y）无效。</li></ul></li><li><strong>相关背景</strong>：非盲试验中，行为变化（如治疗分配意识）可能使A无效时Z仍有效应，破坏&quot;零保持&quot;特性。</li></ul><hr><h4 id="_22-2-a-target-trial-with-sustained-treatment-strategies" tabindex="-1"><a class="header-anchor" href="#_22-2-a-target-trial-with-sustained-treatment-strategies"><span>22.2 A target trial with sustained treatment strategies</span></a></h4><p><strong>Technical Points</strong>:</p><ul><li><strong>核心理论</strong>: <ul><li>持续治疗策略（如抗病毒治疗）的对比需实用主义试验（pragmatic trial），模拟真实条件（无盲法/安慰剂）。</li><li>ITT效应：对比静态策略（z=1, c̄=0 vs z=0, c̄=0）的死亡风险差异。</li><li>方案效应：对比动态策略（g₁: 持续治疗除非禁忌 vs g₀: 永不治疗）的死亡风险差异。</li></ul></li><li><strong>关键公式</strong>: <ul><li>ITT风险差：$$ \\text{Pr}[D_k^{z=1,\\bar{c}_k=\\bar{0}}=1] - \\text{Pr}[D_k^{z=0,\\bar{c}_k=\\bar{0}}=1] $$</li><li>方案效应风险差：$$ \\text{Pr}[D_k^{g_1,\\bar{c}_k=\\bar{0}}=1] - \\text{Pr}[D_k^{g_0,\\bar{c}_k=\\bar{0}}=1] $$</li></ul></li><li><strong>重要概念</strong>: <ul><li><strong>动态策略</strong>：方案效应需包含临床决策逻辑（如毒性停药），非简单静态规则。</li><li><strong>直接效应</strong>：控制中介变量时的效应（Technical Point 22.1）。</li></ul></li><li><strong>应用场景</strong>：HIV患者抗病毒治疗试验（5年死亡风险），时间k=0至59个月。</li></ul><p><strong>细节要点</strong>:</p><ul><li><strong>案例分析</strong>：当实际策略偏离协议（如g₀组在CD4&lt;200时治疗），可概念化为新目标试验的方案效应。</li><li><strong>辅助信息</strong>：完全遵守的试验数据无法模拟新策略效应，非依从性反利于多目标试验模仿。</li><li><strong>相关背景</strong>：纯直接效应（pure direct effect）因跨世界反事实不可识别；主层效应（principal stratum effect）政策相关性低（Technical Point 22.2）。</li></ul><hr><h4 id="_22-3-emulating-a-target-trial-with-sustained-strategies" tabindex="-1"><a class="header-anchor" href="#_22-3-emulating-a-target-trial-with-sustained-strategies"><span>22.3 Emulating a target trial with sustained strategies</span></a></h4><p><strong>Technical Points</strong>:</p><ul><li><strong>核心理论</strong>: <ul><li>观察性分析模仿目标试验需明确：合格标准、随访时间、治疗策略、结局、因果对比。</li><li>ITT的观察性类比：对比治疗初始（A₀=1 vs A₀=0），近似分配效应。</li><li>方案效应定义与目标试验相同，需策略被实际遵循。</li></ul></li><li><strong>重要概念</strong>: <ul><li><strong>时间零点</strong>：随访起始需与目标试验一致（如CD4首次&lt;500cells/μL）。</li><li><strong>克隆-删失-加权</strong>：当个体符合多策略时，克隆副本并IP加权处理删失偏倚。</li></ul></li><li><strong>应用场景</strong>：电子病历数据中模拟多时点合格个体的序列目标试验。</li></ul><p><strong>细节要点</strong>:</p><ul><li><strong>辅助信息</strong>: <ul><li>宽限期（grace period）：允许治疗延迟启动（如3个月内），需克隆处理事件分配。</li><li>&quot;效力-效果&quot;二分法不适用，应明确定义策略而非依赖模糊术语。</li></ul></li><li><strong>相关背景</strong>：观察性分析中，需避免无法转化为干预对比的分析（如第3.5-3.6节）。</li></ul><hr><h4 id="_22-4-time-zero" tabindex="-1"><a class="header-anchor" href="#_22-4-time-zero"><span>22.4 Time zero</span></a></h4><p><strong>Technical Points</strong>:</p><ul><li><strong>核心理论</strong>: <ul><li>时间零点定义：合格标准满足且策略分配时点（如随机化时刻）。</li><li>多合格时点场景：可选用首次/随机时点，或序列试验模拟所有时点（更高效）。</li></ul></li><li><strong>重要概念</strong>: <ul><li><strong>序列试验模拟</strong>：固定时间单位（如月）启动新试验，需bootstrap调整方差。</li><li><strong>策略分配模糊</strong>：克隆个体至兼容策略，事件发生时所有副本死亡。</li></ul></li><li><strong>应用场景</strong>：更年期激素治疗研究（年龄51-65岁多合格时点）。</li></ul><p><strong>细节要点</strong>:</p><ul><li><strong>案例分析</strong>：CD4&lt;500患者中，未治疗者可能符合延迟策略（CD4&lt;350/CD4&lt;200），需克隆处理。</li><li><strong>相关背景</strong>：时间零点错误导致偏倚（如绝经激素研究）。</li></ul><hr><h4 id="_22-5-a-unified-approach-to-answer-what-if-questions-with-data" tabindex="-1"><a class="header-anchor" href="#_22-5-a-unified-approach-to-answer-what-if-questions-with-data"><span>22.5 A unified approach to answer What If questions with data</span></a></h4><p><strong>Technical Points</strong>:</p><ul><li><strong>核心理论</strong>: <ul><li>随机试验与观察性研究差异仅三点：基线混杂、分配概率已知、策略分配已知（Fine Point 22.6）。</li><li>g-方法可统一处理两类研究的方案效应估计（需调整混杂/选择偏倚）。</li></ul></li><li><strong>重要概念</strong>: <ul><li><strong>ITT分析局限</strong>：需g-方法调整失访导致的选择偏倚（如症状影响脱落）。</li><li><strong>方案分析问题</strong>：传统方法忽略动态策略本质、时间混杂、选择偏倚。</li></ul></li><li><strong>应用场景</strong>：长期抗病毒治疗试验中，方案效应估计需时间依赖性协变量调整。</li></ul><p><strong>细节要点</strong>:</p><ul><li><strong>案例分析</strong>：极端案例中（Fine Point 22.7），存在混杂的观察性研究可能优于随机试验（当存在未测量效应修饰）。</li><li><strong>辅助信息</strong>：结合随机试验和观察数据可优化策略（如基于倾向评分设计动态规则）。</li><li><strong>相关背景</strong>：历史将随机试验置于证据金字塔顶端，但长期策略评估中二者方法论应统一。</li></ul><hr><h3 id="关键图表说明" tabindex="-1"><a class="header-anchor" href="#关键图表说明"><span>关键图表说明</span></a></h3><ul><li><strong>图22.1</strong>：未排除限制的路径图（Z→A→Y 和 Z→Y）。</li><li><strong>图22.2</strong>：排除限制下的路径图（无 Z→Y）。</li><li><strong>图22.3</strong>：可测量混杂（L）阻断后门路径。</li><li><strong>图22.4</strong>：方案人群选择（S=1）打开非因果路径。</li></ul><blockquote><p>注：所有总结严格遵循原文，未添加主观推测。数学公式使用LaTeX格式，技术术语保留英文以确保准确性。</p></blockquote>',30))])}const m=i(p,[["render",c]]),T=JSON.parse(`{"path":"/posts/Causal%20inference/What-if%20book%20reading%20notes/response_md/DeepSeek-R1-0528/Chapter_22.html","title":"Chapter_22","lang":"en-US","frontmatter":{"title":"Chapter_22","category":"Causal inference","tags":["DeepSeek-R1-0528","response_md"],"description":"### Chapter 22: TARGET TRIAL EMULATION 22.1 Intention-to-treat effect and per-protocol effect Technical Points: 核心理论: 观察性研究中的因果推断可视为对假设性随机试验（目标试验）的模仿。 意向治疗效应（ITT）定义为分配治疗（Z）对结局（Y...","head":[["script",{"type":"application/ld+json"},"{\\"@context\\":\\"https://schema.org\\",\\"@type\\":\\"Article\\",\\"headline\\":\\"Chapter_22\\",\\"image\\":[\\"\\"],\\"dateModified\\":\\"2025-09-17T03:19:05.000Z\\",\\"author\\":[{\\"@type\\":\\"Person\\",\\"name\\":\\"Aaron L\\",\\"url\\":\\"https://aaronlzm.github.io\\",\\"email\\":\\"lzm_aaron@outlook.com\\"}]}"],["meta",{"property":"og:url","content":"https://aaronlzm.github.io/posts/Causal%20inference/What-if%20book%20reading%20notes/response_md/DeepSeek-R1-0528/Chapter_22.html"}],["meta",{"property":"og:site_name","content":"Aaron's Blog"}],["meta",{"property":"og:title","content":"Chapter_22"}],["meta",{"property":"og:description","content":"### Chapter 22: TARGET TRIAL EMULATION 22.1 Intention-to-treat effect and per-protocol effect Technical Points: 核心理论: 观察性研究中的因果推断可视为对假设性随机试验（目标试验）的模仿。 意向治疗效应（ITT）定义为分配治疗（Z）对结局（Y..."}],["meta",{"property":"og:type","content":"article"}],["meta",{"property":"og:locale","content":"en-US"}],["meta",{"property":"og:updated_time","content":"2025-09-17T03:19:05.000Z"}],["meta",{"property":"article:tag","content":"response_md"}],["meta",{"property":"article:tag","content":"DeepSeek-R1-0528"}],["meta",{"property":"article:modified_time","content":"2025-09-17T03:19:05.000Z"}]]},"git":{"createdTime":1758079145000,"updatedTime":1758079145000,"contributors":[{"name":"lizhimou","username":"lizhimou","email":"lizhimou@bytedance.com","commits":1,"url":"https://github.com/lizhimou"}]},"readingTime":{"minutes":6.45,"words":1935},"filePathRelative":"posts/Causal inference/What-if book reading notes/response_md/DeepSeek-R1-0528/Chapter_22.md","excerpt":"\\n### Chapter 22: TARGET TRIAL EMULATION\\n<h4>22.1 Intention-to-treat effect and per-protocol effect</h4>\\n<p><strong>Technical Points</strong>:</p>\\n<ul>\\n<li><strong>核心理论</strong>:\\n<ul>\\n<li>观察性研究中的因果推断可视为对假设性随机试验（目标试验）的模仿。</li>\\n<li>意向治疗效应（ITT）定义为分配治疗（Z）对结局（Y）的因果效应，通过路径 Z→A→Y（治疗接受）和 Z→Y（行为变化）实现。</li>\\n<li>方案效应（Per-Protocol Effect）定义为所有个体完全遵守分配策略时的因果效应，需调整时间依赖性混杂。</li>\\n</ul>\\n</li>\\n<li><strong>关键公式</strong>:\\n<ul>\\n<li>ITT风险比：$$ \\\\frac{\\\\text{Pr}[Y=1|Z=1]}{\\\\text{Pr}[Y=1|Z=0]} = \\\\frac{\\\\text{Pr}[Y<sup z=\\"0\\">{z=1}=1]}{\\\\text{Pr}[Y</sup>=1]} $$</li>\\n<li>方案效应风险比：$$ \\\\frac{\\\\text{Pr}[Y<sup a=\\"0\\">{a=1}=1]}{\\\\text{Pr}[Y</sup>=1]} $$（在排除限制下）</li>\\n</ul>\\n</li>\\n<li><strong>重要概念</strong>:\\n<ul>\\n<li><strong>排除限制</strong>：当不存在直接路径 Z→Y 时成立（图22.2），双盲安慰剂试验可强制实现。</li>\\n<li><strong>交换性</strong>：随机分配确保 ITT 无混杂（Yᶻ⊥⊥Z），但方案效应需调整混杂（如未测量风险因素U）。</li>\\n</ul>\\n</li>\\n<li><strong>应用场景</strong>:\\n<ul>\\n<li>ITT 用于随机试验的初级分析，方案效应用于评估实际治疗效果（如药物安全性评估）。</li>\\n</ul>\\n</li>\\n</ul>","autoDesc":true}`);export{m as comp,T as data};
